Synaptogenix Inc (SNPX)

[SF Wolf]

Maple tree, I am confident we will see the Ph2b study showing significant improvement in advanced AD patients.

We have a coherent causative theory expounded by a top scientist in the AD research field, Dr. Alkon, and we have a safe drug, Bryostatin, that in animal and Compassionate use patients has shown efficacy.

Neurotrope has not sold any stock into the market prior to results, there is no insider selling, and the recent modest incentive stock option grants to Dr. Alkon and management were not discounted to market price.

The company has mentioned in public forums of applying for fast track FDA status, an open label continuation Ph2b study, a Phase3 study, the Fragile X study and has completed licensing of synthetic Bryostatin from Stanford University research chemists.

Dr. Wilke and Dr. Alkon have publically indicated they would welcome a BP partner and have taken steps to make that possible by increasing the authorized share count allowing the company to sell shares to a BP for equity in NTRP.

All of the above reflects the confidence that the company has in the results to be released Monday morning.